OptimizeRx Corporation (OPRX) News
Filter OPRX News Items
OPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OPRX News Highlights
- OPRX's 30 day story count now stands at 5.
- Over the past 20 days, the trend for OPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about OPRX are DEC.
Latest OPRX News From Around the Web
Below are the latest news stories about OPTIMIZERX CORP that investors may wish to consider to help them evaluate OPRX as an investment opportunity.
Should You Exit OptimizeRx Corp. (OPRX)?Wasatch Global Investors, an investment management firm, released its “Wasatch Micro Cap Value Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark during the quarter. The quality-oriented positioning was the main reason for the strategy’s outperformance in the quarter. In addition, please check the fund’s […] |
OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San FranciscoWALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that executives from the Company will be presenting and participating in one-on-ones at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024. The OptimizeRx presentation will take |
OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
With 74% institutional ownership, OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst the big gunsKey Insights Given the large stake in the stock by institutions, OptimizeRx's stock price might be vulnerable to their... |
Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should KnowThe consensus price target hints at a 41.3% upside potential for OptimizeRx Corp. (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Zacks.com featured highlights Freshpet, OptimizeRx and PinterestFreshpet, OptimizeRx and Pinterest have been highlighted in this Screen of The Week article. |
Why OptimizeRx Corp. (OPRX) Might be Well Poised for a SurgeOptimizeRx Corp. (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%The mean of analysts' price targets for OptimizeRx Corp. (OPRX) points to a 47.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Industry Analysts Just Made A Massive Upgrade To Their OptimizeRx Corporation (NASDAQ:OPRX) Revenue ForecastsOptimizeRx Corporation ( NASDAQ:OPRX ) shareholders will have a reason to smile today, with the analysts making... |
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2023 Earnings Call TranscriptOptimizeRx Corporation (NASDAQ:OPRX) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good morning, everyone and thank you for joining OptimizeRx’s Third Quarter Fiscal 2023 Earnings Discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo. He is joined by company Chief Financial Officer, Ed Stelmakh; President Steve Silvestro; General Counsel Marion […] |